Form 4: Ionis Pharmaceuticals Director Equity Grants Detailed

Spencer R. Berthelsen, a Director at Ionis Pharmaceuticals, reports the grant of stock options and restricted stock units.

Summary

• Spencer R. Berthelsen, a Director at Ionis Pharmaceuticals Inc. (IONS), has filed a Form 4 detailing equity grants received on July 1, 2026.
• The grants include non-qualified stock options to purchase 5,369 shares at an exercise price of $79.19, and 2,301 Restricted Stock Units (RSUs).
• These awards are subject to the company's Non-Employee Director Compensation Policy, with an annual equity compensation limit of $400,000 based on grant date fair value.
• Both the stock options and RSUs vest 100% on the first anniversary of the grant date or the next annual stockholder meeting, whichever is earlier.
• The options are exercisable starting July 1, 2027, and expire on June 30, 2036.
• RSUs will be delivered on July 15th following the vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to routine director compensation and does not provide new financial performance data or strategic shifts.

Positives

• Director Berthelsen received equity grants, aligning his interests with the company's performance.
• The grants are structured with vesting periods, encouraging long-term commitment.
• The compensation policy ensures annual equity awards for non-employee directors do not exceed $400,000 in fair value.

Negatives

• The grants are subject to a cap on annual equity compensation for directors.
• The options are not immediately exercisable, with a vesting period of at least one year.

Risks

• The value of the stock options and RSUs is subject to the future performance of Ionis Pharmaceuticals' stock price.
• Vesting is contingent on continued service as a director or the occurrence of the next annual stockholder meeting.

Future Outlook

The filing details the terms of equity grants to a director, including vesting schedules and exercise periods, which are standard components of executive and director compensation. No specific financial forecasts or business outlooks are provided in this document.

Industry Context

StockSavvy.ai notes that the reporting of equity grants to directors is a standard practice in the pharmaceutical and biotechnology sector, reflecting common compensation structures designed to align executive and director interests with shareholder value.

Stakeholder Impact

• Shareholders: The grants align director interests with long-term company performance, potentially benefiting shareholders if the stock price increases.
• Employees: This filing does not directly impact employees, but reflects the company's compensation practices for its board.
• Management: The filing is a routine disclosure related to director compensation.

Next Steps

• Vesting of stock options and RSUs on the first anniversary of the grant date or the next annual stockholder meeting.
• Exercise of stock options starting July 1, 2027.
• Delivery of RSUs on July 15th following the vesting date.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, SEC Filing, Director Compensation, Equity Grants, Stock Options, Restricted Stock Units, Spencer R. Berthelsen, Beneficial Ownership